Find Funding Opportunities

The purpose of this Funding Opportunity Announcement (FOA) is to further validate promising EEG and eye tracking measures that showed promising performance in the recently-completed Autism Biomarkers Consortium for Clinical Trials (ABC-CT) study. The intent of the FOA is to qualify a set of measures that can be used as biomarkers to reduce heterogeneity, and/or as sensitive and reliable objective measures of social impairment in autism spectrum disorders (ASD) clinical trials. The FOA will support a multi-site consortium to conduct a study with three primary aims to replicate and extend previous characterization of the most promising EEG and eye-tracking measures, incorporating suggestions and guidance from the FDA Biomarkers Qualification Program (BQP). A key goal of the Consortium project is to provide a community resource for broad sharing of all data generated including processed/analyzed data, with rapid and timely deposition of data into the National Database for Autism Research (NDAR). All data generated in this project are expected to be deposited in NDAR and will be accessible for use by all qualified investigators. In addition, blood (DNA) samples are expected to be deposited in the NIMH Repository and Genomics Resource for future research use. The Consortium project will assess the following: (1) whether eye-tracking, EEG paradigms, or a combination of the two, have potential utility as stratification biomarkers and/or as sensitive and reliable measures of change in ASD clinical trials; (2) the relationship (correlation) of validated clinical measures (including measures of social impairment) to eye tracking or EEG paradigms; and (3) the feasibility of collecting the same biomarker measures in a younger cohort.

This FOA invites applications from multidisciplinary teams to perform secondary data analysis, using existing datasets from two or more multi-site clinical research projects, to address scientific and clinical hypotheses relevant to neurological disorders and conditions within the NINDS mission. In this phased funding mechanism, applications are required to systematically and comprehensively perform cross-project data harmonization and curation, assessed using Go/No-go data-quality metrics, prior to funding of the second phase of data analyses. Consistent with the FAIR (findable, accessible, interoperable and reusable) data principles, this funding opportunity expects open-source cataloging of the processes and tools used for harmonization, curation, and analysis, as well as controlled access to the curated datasets.

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

(Reissue of PAR-16-458) The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in postdoctoral position. Based on the early timeframe of eligibility, and the discouragement of inclusion of preliminary data, this NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early fellowship application and timely completion of mentored training of the postdoctoral candidate in a single environment.

The purpose of this FOA is to continue support for the Pediatric HIV/AIDS Cohort Study (PHACS) which addresses the clinical course of perinatally acquired HIV infection in adolescents and young adults and the oral and systemic health consequences of in utero and infant exposure to antiretroviral therapy in cohorts of children in the United States.

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.